Author | Number of cases | Age, years | Surgical operation (cases) | Stage (cases) | Component of tumor | Marker expression of UC component | Adjuvant treatment (cases) | Survival outcome (cases) |
---|---|---|---|---|---|---|---|---|
Silva, EG (2006) [3] | 25 | 51 (median) (range: 30–82) | TH+ BSO (24) | I (14) II (1) III (6) IV (4) | Low grade (10–80%) + UC(20-90%) | Keratin (13 out of 15, focal or diffuse) EMA (all) Neuroendocrine marker (4 out of 15) | Chemotherapy (18) radiation (4) | DOD (15) (median: 7 months) AWPD (6) (6 ~ 8 months) NA(3) |
Shen, Y (2012) [18] | 1 | 51 | TH + BSO + PLND | II | Low grade (80%) + UC(20%) | Negative for EMA focally positive for CK7, CK18 | Vaginal radiation + chemotherapy (CDDP+ DTX + Taxanes) | NA |
Vita, G (2011) [19] | 1 | 45 | TH + BSO | IIIA | Low grade (60%) + UC(40%) | Positive for cytokeratins and EMA | Chemotherapy (CDDP + ATC + Taxanes) | NA |
Wu, ES (2013) [20] | 1 | 62 | NA | NA | NA | NA | Radiation + hormone therapy (Megace alternating with Tamoxifen) | AWPD (3 months) |
Berretta, R (2013) [21] | 1 | 67 | NA | IV | NA | Positive for keratin and negative for neuronal markers | Chemotherapy (CBDCA + Taxol) | NA |
Park, SY (2014) [22] | 1 | 55 | TH + USO + PLND | IB | Low grade (40%) + UC(60%) | Focally positive for CK and EMA | Chemotherapy (PTX + CDDP+DOXO) | DOD (7 months) |
Li, Z (2016) [15] | 13 | 61 (median) | NA | III/IV (12) | NA | Pancytokeratin (10 out of 13) Cam5.2 (8 out of 13) EMA (8 out of 13, weak and patchy) PAX-8 (1 out of 13) | Chemotherapy and radiation (13) | Recurrence or metastasis within 3 years of diagnosis (12) Disease-free after 3 years of diagnosis (1) |
Soyama, H (2016) [23] | 1 | 41 | Supravaginal hysterectomy + USO+partial resection of ileum | IVB | NA | NA | Chemotherapy alone | DOD (7 months) |
Rabban (2016) [24] | 1 | 50 | TH + BSO+PLND | IA | G1(60%) + UC(40%) | Negative for EMA, keratin, PAX-8 | Untreated | Progression after 10 months of surgery |